Learning Objectives
- Implement intensive glucose lowering in T2D for the reduction of microvascular complications.
- Utilize antihyperglycemic agents with proven macrovascular safety by knowing the studies that have CV outcomes.
- Understand the design of ongoing hard outcome studies of antihyperglycemic agents with microvascular and macrovascular endpoints.
- Individualize the pharmacotherapy choice in T2D according to CDA 2013 clinical practice guidelines.
This program has been accredited by the College of Family Physicians of Canada for up to 1 Mainpro-M1 credits
Chair
Ronald M Goldenberg
MD, FRCPC, FACE
Consultant Endocrinologist, North York Hospital and LMC Diabetes & Endocrinology
Faculty
Ronald M Goldenberg
MD, FRCPC, FACE
Consultant Endocrinologist, North York Hospital and LMC Diabetes & Endocrinology
Subodh Verma
MD, PhD, FRCSC, FAHA
Division of Cardiac Surgery, St. Michael’s Hospital
Professor Surgery and Pharmacology & Toxicology, University of Toronto
This program is supported by an educational grant from:
Video Information
- Session ID:177954
- Credit:1 Mainpro-M1 credits
- Post Date:May 12, 2016
- Expiry Date:January 13, 2017
